Navigation Links
TGen-Scottsdale Healthcare clinical trial finds new class of cancer drugs safe and effective
Date:4/9/2013

SCOTTSDALE, Ariz. April 9, 2013 The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen).

Early results from the phase I, first in-human study of an RNA interface (RNAi) drug were announced during the American Association for Cancer Research (AACR) Annual Meeting 2013, April 6-10, in Washington, D.C. The drug, TKM-080301 (also known as TKM-PLK1) is being developed by Tekmira Pharmaceuticals Corporation.

The study was conducted at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with TGen. It found that the RNAi drug acts by silencing the PLK1 gene involved in tumor growth and can be safely administered in humans. Most patients tolerated the drug well; some showed therapeutic benefit.

"RNAi therapies are a unique approach to cancer treatment as they have the potential to 'turn off' the genes' coding for proteins involved in cancer cell division," said Dr. Ramesh K. Ramanathan, Medical Director of Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of TGen. "Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth."

TKM-080301 targets a specific gene called polo-like kinase 1 (PLK1), which codes for a protein involved in tumor cell growth. Prior research has shown that high levels of PLK1 are present in many types of cancer, including many of the more aggressive forms.

"Our preclinical results have shown that by decreasing PLK1 levels in cancer cells, we can stop tumor growth and kill the cancer cells," Dr. Ramanathan said.

He and his colleagues have been enrolling patients with advanced solid tumors or lymphoma into the ongo
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
2. Coral Calcium Company Announces New Offer Amidst Supreme Court Healthcare Decisions
3. Healthcare researchers recognized at SingHealth Duke-NUS Scientific Congress 2012
4. Daily disinfection of isolation rooms reduces contamination of healthcare workers hands
5. Health inequalities could be reduced by more effective healthcare, says new study
6. Healthcare ethics consultants share lessons learned
7. Kessler Foundation stroke expert receives $145,000 grant from Healthcare Foundation of New Jersey
8. Social environmental factors affect rehospitalization risk in home healthcare patients
9. TGen, Scottsdale Healthcare lead worldwide study of new drug for patients with pancreatic cancer
10. CWRU dental and nursing students collaborate for one-stop healthcare
11. University Hospitals & Philips Healthcare to showcase imaging technology at Cleveland Medical Mart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... CareSpan USA, Inc. announced today at the ... services agreement with Avera eCARE, a leading healthcare system ... Clinic in multiple states where Avera eCARE is licensed. ... joint services in remote and rural parts of North ... licensed. The two companies’ strategy is to focus on ...
(Date:9/21/2014)... Dallas, Texas (PRWEB) September 22, 2014 ... was originally launched in 1997, and is used ... children and adults. Its active ingredient, budesonide, is ... the corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the ... older than six years of age, Pulmicort Respules ...
(Date:9/21/2014)... an allergy to peanuts than raw peanuts, suggests an ... that specific chemical changes caused by the high temperatures ... body,s immune system, ,priming, the body to set off ... any peanuts. , The results might explain the difference ... the Western world compared to populations in East Asia, ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... enabled more generic drugs to inundate the market, thereby ... Pharmaceutical Manufacturing industry. According to data from Industry ... has cost the industry $1.8 and $2.5 billion in ... brand-name drugs losing patent exclusivity, which has hampered revenue ...
(Date:9/21/2014)... "I want to help people who ... haven’t the money for chiropractors," said an inventor from ... a product for myself." , The Stretch is a ... thigh muscles and align the spine properly. It improves ... of pinched nerves. Compact and easy to use, it's ...
Breaking Medicine News(10 mins):Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Dry roasting could help trigger peanut allergy 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3
... Oral Suspension Also Approved--, WILMINGTON, Del., Feb. 28 ... and Drug Administration (FDA) has,approved the use of NEXIUM(R) ... for the short-term treatment of gastroesophageal reflux,disease (GERD) for ... unmet,need for pediatric patients., NEXIUM received approval in ...
... Hospital has entered,into an agreement with VISICU, Inc., ... and remote monitoring tools, eICU,technology enables off-site critical ... around the clock. The voice, video and data,technology ... rates and shorten hospital length of stay., ...
... Education, Body Mass Index training events for, physicians and ... ... adults, INDIANAPOLIS, Feb. 28 With obesity at the forefront ... the Indiana Department of Health today announced that they will be,hosting ...
... (NEWARK, N.J., Feb. 28, 2008) New Jersey State ... Administration Research Education) Award for Excellence in Research to ... Flynn, assistant professor at the College of Nursing at ... honored with three other C.A.R.E. award recipients during the ...
... technologies and ... medical advancements, AUSTIN, Texas, Feb. ... officially opened the expansion of its,heart hospital today with the introduction ... as the number one overall,cardiac program in the State of Texas ...
... CHICAGO, Feb. 28 The Female Health Company,(Amex: ... John Snow, Inc., which,implements the USAID | DELIVER PROJECT, ... the United States Agency for International,Development (USAID) programs., ... international donors,of contraceptives and condoms. The Agency developed an ...
Cached Medicine News:Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 2Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 3Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 4Health News:FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old 5Health News:The Christ Hospital and VISICU Sign Agreement to Implement eICU(R) Program 2Health News:Anthem Blue Cross and Blue Shield Teams with the State of Indiana to Combat Obesity 2Health News:Anthem Blue Cross and Blue Shield Teams with the State of Indiana to Combat Obesity 3Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 2Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 3Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 4Health News:The Female Health Company Receives USAID DELIVER PROJECT Order for 6.1 Million Units 2
(Date:9/19/2014)... Sept. 19, 2014 "Copay coupons," ... sales of brand drugs among patients with prescription drug ... to a new report  from the Department ... Inspector General (OIG). Federal anti-kickback laws prohibit suppliers ... are subsidized by the federal government. ...
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... 2014 According to the ... Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications ... - Global Forecast to 2019" published by MarketsandMarkets, the ... $19,786.3 Million by 2019 from $14,240.0 Million in ... to 2019. Browse 74 market data ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... SphygmoCor system plays key role in discovery, ... A,new study of more than 10,000 patients, conducted ... United Kingdom using AtCor Medical Holdings,Limited,s SphygmoCor(R) has ... as having "high normal" systolic blood pressure through,traditional ...
... 28 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... oral and,poster presentations on its Cobalamin(TM) technology ... to Clinical Practice, taking,place from May 26-28 ... B12-Polymer Conjugates as Constructs for Targeted Tumor ...
Cached Medicine Technology:New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk 2New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk 3Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium 2Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: